Volume 7 Supplement 1

25th European Workshop for Rheumatology Research

Open Access

Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumor necrosis factor alpha antibody infliximab

  • X Baraliakos1,
  • J Listing2,
  • M Rudwaleit3,
  • J Brandt1,
  • J Sieper3 and
  • J Braun1
Arthritis Research & Therapy20057(Suppl 1):P31

DOI: 10.1186/ar1552

Received: 11 January 2005

Published: 17 February 2005


Anti-tumor necrosis factor therapy is clinically efficacious in patients with active ankylosing spondylitis (AS) and leads to improvement of spinal inflammation, as assessed by magnetic resonance imaging. It is unclear whether anti-tumor necrosis factor therapy has influence on chronic spinal changes in AS.


To analyze the effect of infliximab on the radiographic course of AS over 2 years.


Complete sets of lateral radiographs of the cervical and the lumbar spine were available from 82 patients from two sources: 41 patients (group 1) had been treated with infliximab (5 mg/kg/6 weeks) as part of a recent randomized controlled trial, and 41 patients (group 2) were part of the early German AS cohort (GESPIC), without controlled interventions. Radiographs were performed at baseline and after 2 years and were scored by the modified SASSS.


Patients in the infliximab group were older, had a longer disease duration and more radiographic damage at baseline. The mean modified SASSS change was 0.4 (± 2.7) and 0.7 (± 3.4) for group 1 and group 2, respectively (P = not significant). Radiographic damage at baseline was a predictor for more radiographic progression. Patients with baseline damage who were treated with infliximab showed a trend for less radiographic progression. There were no correlations between clinical parameters and radiographic progression.


AS patients treated with infliximab showed somewhat less radiographic progression after 2 years. Patients with prevalent radiographic damage are prone to develop more damage over time. Infliximab may decelerate radiographic progression in such patients. Larger studies are needed to prove that anti-tumor necrosis factor therapy inhibits structural damage.



This abstract is eligible for application for a postgraduate student fellowship.

Authors’ Affiliations

Rheumazentrum Ruhrgebiet
German Rheumatism Research Center
Rheumatology, Charité


© BioMed Central Ltd 2005